Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Retisert (Bausch & Lomb/Control Delivery Systems).

Lyndell L Lim¹, Justine R Smith, James T Rosenbaum

¹Casey Eye Institute, Oregon Health & Science University, Portland, OR 97201, USA. liml@ohsu.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|November 30, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity.

npj drug discovery·2026

Same author

Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis.

Arthritis research & therapy·2025

Same author

Complexities in the Terminology Used for Describing, Diagnosing, and Classifying Retinal Vasculitis: A Scoping Review from the International Uveitis Study Group (IUSG) Retinal Vasculitis Study (ReViSe)-Report 6.

Ocular immunology and inflammation·2025

Same author

Microbiome signatures and their role in uveitis: Pathogenesis, diagnostics, and therapeutic perspectives.

Progress in retinal and eye research·2025

Same author

Clinical trials and quasi-experimental studies in the treatment of noninfectious retinal vasculitis: A systematic review from the International Uveitis Study Group (IUSG) Retinal Vasculitis Study (ReViSe) - Report 4.

Survey of ophthalmology·2025

Same author

Work-up in patients with retinal vasculitis: A systematic review and meta-analysis: International Uveitis Study Group (IUSG) Retinal Vasculitis Study (ReViSe) Report 2.

Survey of ophthalmology·2025

Retisert, a sustained release intraocular implant, treats chronic non-infectious uveitis in the posterior eye. This fluocinolone acetonide implant offers a new therapeutic option for patients.

Area of Science:

Ophthalmology
Drug Delivery Systems
Inflammation Research

Background:

Chronic non-infectious uveitis affecting the posterior segment of the eye is a significant cause of vision loss.
Current treatments may have limitations in efficacy or systemic side effects.

Purpose of the Study:

To introduce Retisert (Envision TD), a novel sustained release intraocular implant.
To highlight its indication for treating chronic non-infectious posterior uveitis.

Main Methods:

Development and launch of Retisert, an intraocular implant.
Utilizes fluocinolone acetonide for sustained release.

Main Results:

Retisert has been developed and launched in the US market.

Related Experiment Videos

It is specifically designed for ocular drug delivery.

Conclusions:

Retisert provides a new sustained release treatment option for chronic non-infectious uveitis.
The implant targets the posterior segment of the eye for localized therapy.